# OABI earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/OABI) · [Earnings tab](https://www.lopjlb.com/stock/OABI?tab=earnings) Updated: 2026-10-31T06:58:21 Quarters analyzed: 8 ## Cross-quarter narrative Across the eight earnings calls OmniAb moved from a vague, low‑visibility outlook in late 2024 to increasingly specific guidance and multiple technology launches by late 2026. Partner demand accelerated, with active partners rising from 95 to 111 and programs expanding from 378 to 433, while clinical‑stage assets grew to 34. The company introduced the Exploration partner access program, the xPloration instrument, OmniUltra and OmniTides platforms, each gaining traction but also exposing adoption risk and consumable‑pull‑through uncertainty. Cost discipline improved steadily; operating expenses fell year‑over‑year, headcount cuts were executed, and a $30 million private placement bolstered the balance sheet. Revenue remained lumpy, dropping in several quarters and driven by milestone timing, which increasingly shifted to 2026, creating near‑term visibility gaps. Cash‑flow pressure persisted despite higher guidance ($35‑39 million for 2026) and large contracted milestones ($350 million). New concerns emerged around market fundraising conditions, royalty‑structure opacity, and scaling of xPloration consumables, while earlier fears of cash burn and partner attrition remained recurring. ## Latest CallCard · Q3 OmniAb Q3 2026: revenue $4M vs $2.2M prior year; 9-month $31.8M vs $10.3M; raised 2026 revenue guidance to $35-39M, lowered op ex; new Lilly ion channel deal up to $370M milestones; xPloration expanding, OmniTides launched; batoclimab approved in China (4th drug); 111 partners, 433 programs, 34 clin **Guidance:** raised — Revenue guidance raised to $35-39M from $32-36M; cost and operating expense guidance lowered to $83-87M from $84-88M; cash cost guidance lowered to $50-54M from $51-55M; year-end cash projected $53-57M, implying breakeven net cash flow for 2026. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Management highlighted strong performance, raised guidance, announced major Lilly deal, launched new platforms (xPloration, OmniTides), and emphasized durable revenue streams and partner growth. ### Demand visibility Strong partner utilization and program growth with 111 active partners, 433 programs, 34 clinical-stage assets, and 19 upcoming readouts over 15 months. Active partners increased to 111 (net +1 Q/Q). Active programs rose to 433 (+26 YTD). 9 of top 10 pharma are partners. 19 clinical readouts expected over next 15 months within $340M remaining milestone pool. xPloration pipeline growing with placements across big pharma, CROs, biotech. New ion channel service agreements signed late 2025/early 2026 driving service revenue. Lilly collaboration expected to contribute service revenue in Q4. ### Margins / costs Operating expenses decreasing due to efficiencies; xPloration investments offset by savings elsewhere; non-GAAP cash costs stable. Q3 total cost and operating expense flat at $20.4M YoY. YTD operating expense $62.7M vs $63.5M prior year, reflecting efficiencies. R&D and G&A decreased, partially offset by higher other expense (cost of sales from instrument sales). Non-GAAP cash costs similar period-over-period. Full-year op ex guidance reduced by $1M. ### Capital allocation Investing in xPloration growth while reallocating resources from core antibody business; no dramatic op ex increases expected. Core antibody business rightsized; xPloration investments funded by savings in other areas. Management allocates dollars where they see returns. No expectation of dramatic operating expense increases based on current projections. Focus on durable revenue streams: milestones, royalties, service, xPloration recurring revenue. ### Milestones - **Eli Lilly ion channel collaboration** [new]: Announced Q3 2026; upfront received; up to $370M milestones plus tiered royalties; service revenue expected Q4 2026. - **xPloration platform commercial expansion** [on_track]: Placed another unit with top global big pharma in Q3; revenue guidance $2-3M 2026, doubling 2027, doubling again 2028; recurring revenue from consumables, software, service to ramp. - **OmniTides peptide discovery offering** [new]: Launched at Investor Day; powered by OmniUltra transgenic chicken; attracting deep collaborators, especially in metabolic space; diversifies partner base and therapeutic areas. - **Batoclimab China approval** [delivered]: Approved by NMPA for generalized myasthenia gravis (anti-AChR antibody positive); fourth drug approved from platform; Harbour Biomed preparing launch; royalty impact TBD. - **TEV-'408 (celiac/vitiligo)** [on_track]: Positive celiac data; Teva sees $1.5-2B peak sales in celiac, ~$1B in vitiligo; Fast Track designation; also exploring alopecia areata, EoE, atopic dermatitis. - **IMVT-1402, Precemtabart tocentecan** [on_track]: Described as pipeline-in-a-product assets with first-in-class/best-in-class potential; partners highly committed to rapid advancement. - **19 clinical readouts over next 15 months** [on_track]: Busiest clinical readout calendar ever; within $340M remaining milestone pool from active clinical programs. - **xPloration revenue doubling 2027 and 2028** [on_track]: Guidance: $2-3M 2026, double 2027, double again 2028; recurring revenue from consumables, software, service to become long-term growth driver. ### Fears / risks - **Milestone revenue lumpiness**: Milestone revenue varies quarter-to-quarter; front-end loaded in 2026 vs back-half loaded in 2025; timing dependent on partner program progress. - **xPloration scaling uncertainty**: Capital budgeting cycles 12-18 months; consumable pull-through not yet stabilized; revenue doubling targets depend on instrument placements and usage ramp. - **Royalty revenue timing uncertain**: Batoclimab China pricing unknown; IMVT-1402 royalties expected late 2028; royalties not expected to be majority revenue contributor for several years. - **Program attrition**: 12 program terminations YTD 2026; attrition normal as partners refine pipelines and R&D priorities. - **Service revenue dependence on ion channel deals**: Service revenue increase driven by ion channel agreements signed late 2025/early 2026; Lilly contribution starts Q4; sustainability depends on new deals. - **xPloration consumable adoption variability**: Pull-through differs by customer type (academia vs large pharma vs CRO); early days to assess recurring revenue stability. - **AI integration execution risk**: xPloration aims to fit AI-enabled discovery workflows; success depends on integration with automated lab systems and data quality. - **Partner concentration**: 9 of top 10 pharma are partners, but revenue still heavily milestone-dependent; diversification into royalties and recurring streams gradual. ### Key quotes > “We have been and continue to be very active from a licensing perspective and announced a major new deal in the quarter with Eli Lilly for a novel ion channel program.” > “We now expect total revenue to be in the range of $35 million to $39 million, which is up from $32 million to $36 million previously.” > “we expect xPloration revenue to double in 2027 and to double again in 2028.” > “batoclimab, which is shown here on Slide number 9, in the registration column in blue, received approval in China for the treatment of generalized myasthenia gravis” > “for the next couple of years, milestones, we would expect would still be the biggest contributor to our overall revenue stream.” ## Quarter one-liners - **2026 Q3:** OmniAb Q3 2026: revenue $4M vs $2.2M prior year; 9-month $31.8M vs $10.3M; raised 2026 revenue guidance to $35-39M, lowered op ex; new Lilly ion channel deal up to $370M milestones; xPloration expanding, OmniTides launched; batoclimab approved in China (4th drug); 111 partners, 433 programs, 34 clin - **2026 Q2:** — - **2026 Q1:** OmniAb raises 2026 revenue guidance to $28-33M on strong Q1 milestones; 32 clinical programs advance with $350M contracted milestones; OmniUltra and xPloration gaining traction. - **2025 Q4:** OmniAb reports strong partner growth, launches OmniUltra and xPloration, but revenue fell in Q4; guidance for 2026 targets $25-30M with focus on cost discipline and cash‑flow positivity. - **2025 Q3:** OmniAb reports strong partner demand, launches OmniUltra in December, sees xPloration traction, but notes some 2025 milestones shifting to 2026 and limited near‑term revenue visibility. - **2025 Q2:** OmniAb Q2 2025 saw revenue drop to $3.9M as milestones fell, but management highlighted strong partner demand, the new xPloration instrument launch and maintained 2025 guidance despite ongoing cost cuts and headcount reductions. - **2025 Q1:** OmniAb Q1 2025: revenue $4.2M vs $3.8M YoY, net loss $18.2M, 95 active partners, 378 programs, launched Exploration partner access program ($500k instrument + consumables/subscription), maintained 2025 guidance of $20-25M revenue and $85-95M op ex. - **2024 Q4:** — ## Theme arcs - **Partner demand and program growth** (improving): Active partners grew from 95 to 111 and programs from 378 to 433, with clinical programs expanding to 34 - **Revenue volatility** (deteriorating): Quarterly revenue fluctuated and fell in multiple periods despite raised guidance - **Milestone timing uncertainty** (deteriorating): Partner milestones repeatedly delayed to 2026, reducing near‑term revenue visibility - **Cost discipline and expense reduction** (improving): Operating expenses decreased each quarter, headcount reductions and a $30 M placement improved cash position - **Cash position and financing** (new): Private placement and later larger milestone contracts added liquidity, but cash‑burn concerns persisted - **Technology platform adoption** (improving): Launches of Exploration, xPloration, OmniUltra and OmniTides showed traction but introduced adoption risk - **Royalty structure uncertainty** (new): Timing and mix of tiered versus flat royalties remained undisclosed - **Market fundraising environment** (new): Potential slowdown in external fundraising noted as a risk to partner program growth ## Guidance path 2024 Q4:vague → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:maintained → 2025 Q4:maintained → 2026 Q1:raised → 2026 Q2:vague → 2026 Q3:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/OABI`